Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting
Abstract
The increasing usage of rituximab in the management of non-Hodgkin lymphoma (NHL) has created huge logistical challenges with respect to the delivery of this time- and labor-intensive drug. To address these challenges, we developed and tested the feasibility of a 90-minute infusion schedule for rituximab (20% of the dose administered in the first 30 minutes, remaining 80% administered over 60 minutes). A safety analysis performed in 150 patients receiving rituximab with corticosteroid-containing chemotherapy and 56 patients receiving rituximab as maintenance therapy demonstrated that this schedule was well tolerated, with no grade 3 or 4 infusion reactions observed. In addition, no increase in minor reactions was noted. More than 1200 patients have been treated with this rapid rituximab infusion schedule in the province of British Columbia (BC), demonstrating its safety in the community setting. The adoption of this 90-minute schedule as standard practice has had a positive impact on resource utilization.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The increasing use of rituximab in the treatment of hematological malignancies in both induction and maintenance settings has placed a major burden on infusion services, resulting in long waiting times for eligible patients.
“The increasing use of the mAb rituximab in the treatment of hematological malignancies in both induction and maintenance settings has placed a major burden on infusion services, resulting in long waiting times for eligible patients [49].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [49]
Cites
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574 · see citing works
McLaughlin, P. J., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence‐Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,752 · see citing works
Marcus, R. E. (2004) · Blood · doi:10.1182/blood-2004-08-3175 · Cited by 972 · see citing works
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657 · see citing works
van Oers, M. H. J., Klasa, R. J., Marcus, R. E., et al. (2006) · Blood · doi:10.1182/blood-2006-05-021113 · Cited by 593 · see citing works
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-04-1258 · Cited by 571 · see citing works
Byrd, J. C., Murphy, T., Howard, R. S., Lucas, M. S., Goodrich, A., Park, K., Pearson, M., Waselenko, J. K., Ling, G. S. F., Grever, M. R., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2153 · Cited by 508 · see citing works
Salar, A., Casao, D., Cervera, M., et al. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2006.00713.x · Cited by 45 · see citing works
Accelerated Delivery of Rituximab Is Safe on an Out-Patient Basis.
Middleton, H., Mollee, P. N., Bird, R. J., et al. (2005) · Blood · doi:10.1182/blood.v106.11.4777.4777 · Cited by 18 · see citing works
“One Hour” Rituximab Infusion Is Safe and Improves Patient Care and Outpatient Unit Management.
Aurran‐Schleinitz, T., Gravis, G., Vittot, M., et al. (2005) · Blood · doi:10.1182/blood.v106.11.4759.4759 · Cited by 18 · see citing works
Sehn, L. H., Donaldson, J., Filewich, A., et al. (2004) · Blood · doi:10.1182/blood.v104.11.1407.1407 · Cited by 13 · see citing works
Self-citationGhielmini, M. E. G., Negretti, L., Lerch, E., et al. (2005) · Blood · doi:10.1182/blood.v106.11.2451.2451 · Cited by 8 · see citing works
The PIG-A Gene Is Hypermutable in Lymphoid Neoplasms.
DiTata, K., & Araten, D. J. (2006) · Blood · doi:10.1182/blood.v108.11.2395.2395 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447 · see citing works
Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
Shpilberg, O., & Jackisch, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.371 · Cited by 138 · see citing works
- Authors
- Sehn, L. H., Donaldson, J., Filewich, A., Fitzgerald, C., Gill, K. K., Runzer, N., Searle, B., Souliere, S., Spinelli, J. J., Sutherland, J., & Connors, J. M.
- Affiliations
- BC Cancer Agency (CA)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2007-01-23
- Volume
- 109
- Issue
- 10
- Pages
- 4171-4173
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2094502152
- Cited by
- 100
- References
- 13
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 3 · 2022: 5 · 2021: 5 · 2020: 12 · 2018: 4 · 2017: 5 · 2016: 3 · 2015: 4 · 2014: 9 · 2013: 8 · 2012: 6
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- BC Cancer Agency
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Keywords
- rituximab, non-Hodgkin lymphoma, maintenance therapy, infusion reactions, drug safety, community pharmacy, resource utilization (health care)
- MeSH terms
- Rituximab, Adrenal Cortex Hormones, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Feasibility Studies, Hospitals, Community, Humans, Infusion Pumps, Lymphoma, Non-Hodgkin, Middle Aged, Time Factors, Chemotherapy, Adjuvant, Antibodies, Monoclonal, Murine-Derived
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
